机构：[1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics,Beijing, China[2]Institute of Biomedical Engineering, School of Medical Instrument and Food Engineering, University of Shanghai for Science andTechnology, Shanghai, China[3]Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East ChinaNormal University, Shanghai, China[4]Department of Orthopedic Oncology, Changzheng Hospital, The Second Military Medical University,Shanghai, China[5]Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou,Sichuan, China[6]Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, InternationalCampus, Zhejiang University, Haining, China[7]Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang UniversitySchool of Medicine, Zhejiang University, Hangzhou, China[8]Department of Molecular and Cellular Biology, Dan L.Duncan Cancer Center, Baylor Collegeof Medicine, One Baylor Plaza, Houston, TX, USA[9]Cancer Center, Massachusetts General Hospital, Boston, MA, USA[10]Shanghai ChangningMaternity and Infant Health Hospital, Shanghai, China[11]Division of Hematology & Medical Oncology, Laura and Isaac Perlmutter Cancer Center, NewYork University Langone Medical Center, New York, NY, USA[12]Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University,School of Medicine, Shanghai, China
第一作者机构：[1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics,Beijing, China
共同第一作者：
通讯作者：
通讯机构：[3]Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East ChinaNormal University, Shanghai, China[5]Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou,Sichuan, China[6]Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, InternationalCampus, Zhejiang University, Haining, China[7]Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital, Zhejiang UniversitySchool of Medicine, Zhejiang University, Hangzhou, China[8]Department of Molecular and Cellular Biology, Dan L.Duncan Cancer Center, Baylor Collegeof Medicine, One Baylor Plaza, Houston, TX, USA
推荐引用方式(GB/T 7714)：
Tan Xiaohong,Tong Lu,Li Lin,et al.Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation.[J].NATURE COMMUNICATIONS.2021,12(1):doi:10.1038/s41467-021-24898-9.
APA：
Tan Xiaohong,Tong Lu,Li Lin,Xu Jinjin,Xie Shaofang...&Li Xiaotao.(2021).Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation..NATURE COMMUNICATIONS,12,(1)
MLA：
Tan Xiaohong,et al."Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulation.".NATURE COMMUNICATIONS 12..1(2021)
综合性期刊